Novo Nordisk raises outlook on continued GLP-1 demand
The Danish drugmaker lifted guidance, pointing to sustained uptake of its incretin franchise.
TR
By Tom Reyes · Markets Editor
May 6 03:00 ETSource: finance.yahoo.com
The wire
- 01Novo Nordisk raised its financial outlook, citing strong ongoing demand for its GLP-1 products.
- 02Guidance changes from the largest incretin maker signal how supply and prescribing volumes are trending for prescribers and pharmacies.
- 03Detailed figures by product and region were not given in the report; the full earnings disclosure would be needed to assess drivers.
From the source
Read at finance.yahoo.comNovo Nordisk Raises Outlook as GLP-1 Demand Stays Strong
